INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Go Bigger, Stay On Target, And Develop The Cell Lines That Get The Job Done

  Build the most relevant cell line for your studies with the ability to insert 20+ kb of DNA site specifically, in single copy, and at efficiencies approaching 100% after selection.

• AI For Faster, Smarter Gene Therapy Development And Manufacturing

  Here, we highlight real-world applications of AI in gene therapy, providing case studies and addressing the challenges and prerequisites for successful implementation.

• How You And Your CDMO Should Leverage Contamination Control Strategies For Competitive Advantage

  It is no longer sufficient to just meet compliance requirements; a proactive, risk-based approach to contamination control is now a differentiating factor that enhances operational efficiency and more. For biotech companies evaluating CDMOs, this shift is critical.

• August 2025 — CDMO Opportunities And Threats Report

  Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

• CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D.

  Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

• Protecting The Foundation Of Biologics With Flexible, Scalable Cell Banking

  Safeguard your cell banks with secure, compliant storage and streamlined delivery solutions that keep manufacturing on schedule and therapies moving forward.

• ATMP Development In 2025: Promise, Pressure, And The Push To Scale

  Drive the next wave of cell and gene therapy innovation by overcoming operational, funding, and regulatory challenges to deliver life-changing treatments to patients faster.

• Built For Speed: How To Deliver Without Compromise

  Ensure fast, reliable, temperature-controlled logistics with a global infrastructure designed to protect critical biologic materials and keep development programs running smoothly and on schedule.

• Take A Virtual Tour Of Our Cell Line Development Centre Of Excellence

  Explore the advanced capabilities of our Cell Line Development Center in Ulm, Germany. From expert teams to streamlined processes, discover how we support biopharma innovation.

• Extractables, Leachables, And Risk: Ensuring Safety In Pharma Manufacturing

  This session is designed for teams developing new products, optimizing processes, or preparing regulatory submissions, and will provide practical tools for a better approach to E&L management.